Baseline characteristics of the 51 patients used for ctDNA analysis
| Baseline characteristics . | N (%) or median (range) . |
|---|---|
| Total, N (%) | 51 (100) |
| Age, median (range), y | 53 (17-68) |
| Male, N (%) | 29 (56.9) |
| Diagnosis, N (%) | |
| AML | 37 (72.5) |
| De novo AML | 15 (29.4) |
| Secondary AML | 22 (43.1) |
| MDS | 14 (27.5) |
| Stem cell source, N (%) | |
| BM | 4 (7.8) |
| Cord blood | 47 (92.2) |
| Disease status at alloSCT, N (%) | |
| CR | 8 (15.7) |
| Relapse or refractory | 25 (49.0) |
| No previous treatment | 18 (35.3) |
| Cytogenetics, N (%) | |
| Normal karyotype | 19 (37.3) |
| Aberrant karyotype | 32 (62.7) |
| −7/del7q | 8 (15.7) |
| +8 | 7 (13.7) |
| Complex karyotype | 15 (29.4) |
| Relapsed patients after alloSCT, N (%) | 16 (31.4) |
| Median follow-up (range), mo | 32 (4-102) |
| Baseline characteristics . | N (%) or median (range) . |
|---|---|
| Total, N (%) | 51 (100) |
| Age, median (range), y | 53 (17-68) |
| Male, N (%) | 29 (56.9) |
| Diagnosis, N (%) | |
| AML | 37 (72.5) |
| De novo AML | 15 (29.4) |
| Secondary AML | 22 (43.1) |
| MDS | 14 (27.5) |
| Stem cell source, N (%) | |
| BM | 4 (7.8) |
| Cord blood | 47 (92.2) |
| Disease status at alloSCT, N (%) | |
| CR | 8 (15.7) |
| Relapse or refractory | 25 (49.0) |
| No previous treatment | 18 (35.3) |
| Cytogenetics, N (%) | |
| Normal karyotype | 19 (37.3) |
| Aberrant karyotype | 32 (62.7) |
| −7/del7q | 8 (15.7) |
| +8 | 7 (13.7) |
| Complex karyotype | 15 (29.4) |
| Relapsed patients after alloSCT, N (%) | 16 (31.4) |
| Median follow-up (range), mo | 32 (4-102) |
CR, complete remission.